Evaluation of clinical prognostic factors in T1 N0 M0 head and neck basal cell carcinoma.
This retrospective study was carried out to assess the clinical outcome of stage I (ie, T1 N0 M0) head and neck basal cell carcinoma (HNBCC) and verify the impact of some clinical parameters on prognosis. The cases of 220 patients with stage I (ie, T1 N0 M0) histologically proven HNBCC were analyzed.The global disease-specific survival rate at 36 months was 100%, irrespective of the type of surgery, and thus, it was demonstrated that radical tumor resection is a viable procedure for stage I HNBCC. However, 11 (5%) of 220 cases had a recurrence. A second procedure was performed in 10 (90.9%) of 11 cases. In 3 of the 10 patients operated on twice (30%), a second recurrence was detected. Thus, a second surgical procedure on a recurring tumor is possible, but the multimodality treatment regimen should be considered for recurring tumors.
Morselli
Paolo
P
Department of Plastic Surgery, Ospedale S Orsola, Bologna, Italy.
Zollino
Ilaria
I
Pinto
Valentina
V
Brunelli
Giorgio
G
Carinci
Francesco
F
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002280:Basal Cell Carcinoma / Q000473:pathology / Q000601:surgery*; D002610:Cheek / Q000601:surgery; D018572:Disease-Free Survival; D004428:Ear Neoplasms / Q000601:surgery; D004431:Ear, External / Q000601:surgery; D005142:Eyelid Neoplasms / Q000601:surgery; D005153:Facial Neoplasms / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000473:pathology / Q000601:surgery*; D006801:Humans; D008048:Lip Neoplasms / Q000601:surgery; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D009367:Neoplasm Staging; D009669:Nose Neoplasms / Q000601:surgery; D011379:Prognosis; D012086:Reoperation; D012189:Retrospective Studies; D016896:Treatment Outcome